Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Transarterial chemoembolization (TACE) is the standard locoregional therapy for unresectable HCC but is limited by high recurrence and hepatic toxicity. Low-molecular-weight fucoidan (LMF), a sulfated polysaccharide from brown seaweed, has anticancer and hepatoprotective properties. This study assessed whether LMF enhances tumour response and preserves liver function when combined with TACE.

Methods

In this randomised, double-blind, placebo-controlled trial, 82 patients with unresectable HCC were randomly assigned (1:1) to receive LMF (4.4 g twice daily) or placebo for 6 months in addition to TACE. Tumour response was assessed using modified RECIST criteria, and liver function was monit

SUBMITTER: Zou Y 

PROVIDER: S-EPMC12442522 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature